F-Prime Capital

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community. Who We AreOur flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence and, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. Beyond CapitalRA Capital offers its portfolio companies much more than capital to help them grow, make decisions, and succeed. We:Serve on boards of private and public companies and host board meetings at our offices Help recruit executives and board members Provide access to TechAtlas maps and expertise Prioritize indications and targets based on their feasibility and value given current scientific knowledge, unmet needs, and emerging competition Monitor for new applications and complementary technologies Create custom maps that lay out a company’s competition and unrealized opportunities Provide extra analytical bandwidth across our large team (e.g., analyze literature, provide insights from scientific and investor conferences) Assist with grant writing and preparation of scientific publications Interview clinicians and key opinion leaders (KOLs) Host advisory boards Facilitate partnership or acquisition discussions with larger companies Help design (or redesign) a corporate slide deck or website, leveraging in-house writing and graphics teams Make introductions to other investors Anchor subsequent financings and set the pace for closing Help select bankers for financings and M&A We also provide a growing suite of Innovator Resources to the broader ecosystem, with more hands-on support for our portfolio companies, management teams, and boards. These resources include: a comprehensive reference guide to conducting successful biotech board meetings; a data-driven guide to how to conduct a logical IPO based on first principles of price discovery and shareholder alignment; and a roadmap for how to convey your company’s unique Equity Value Proposition to employees (because they are also your investors). We’re available to coach you through a pitch, provide feedback on a deck, and partner with you to refine strategy or messaging at every stage. Additionally, we helped to found and continue to support No Patient Left Behind, a non-profit dedicated to promoting affordability of today’s medicines and the development of better ones. More specifically, NPLB advocates for insurance reforms that would allow all patients to afford the treatments they need, draws attention to the full societal value of all medicines and the merits of ensuring that all drugs go generic without delay, and educates lawmakers and the public about the workings of the biomedical ecosystem to protect it against misguided policies. Translation & HuntingRA Capital offers Executive-In-Residence (EIR) and venture partner programs for experienced professionals seeking thought partners. We welcome experienced drug hunters searching for technologies/candidates and looking to start new companies to collaborate with our team, explore the capabilities of our in-house incubator, and take advantage of the breadth and depth of our TechAtlas platform. RAVen, our in-house incubator, provides a collaborative platform for drug hunters and company builders to explore both the novel and the re-imagined. Discoveries and improvements in chemistry, molecular and cellular biology, and materials science create novel capabilities that may address unsolved challenges. Our understanding of fundamental biology is constantly evolving, revealing new applications for existing technologies and partially-developed drug candidates. Programs we consider worthwhile may form the basis for a new venture. We believe that when a business proposition is framed correctly, the capital markets have adequate resources and understanding to fund proper experimental design and solution development without forcing companies to cut corners. Furthermore, we have collaborated extensively with other funds that share our philosophy to enable ambitious and capital-intensive endeavors. Our ValuesWe at RA Capital are introspective and deliberate about the ways in which we engage with each other and those outside our firm. Our values represent a set of clear parameters by which we create working relationships founded on trust, collaboration, diligence, and integrity.We originate conviction. We do not borrow it from others. We expect and strive to inspire the best in everyone. We embrace the unfamiliar. We do not let convention stand in the way of what is right. We learn collaboratively. We have a bias for action. We are persistently curious and humbled by what is left to learn. We are data-driven and challenge assumptions. We preserve the ability to change our mind. We admit our mistakes and share lessons learned. We address the elephant in the room. We value our relationships and are positive, respectful, and open-minded. We take fun seriously.

We partner with companies that create entirely new markets. For more than 25 years, and longer than almost any other investor in the country, our Principals have financed and helped build more successful healthcare industry "firsts" and companies that became market leaders. We invest on behalf of many of the largest healthcare organizations in the country, many of healthcare's most accomplished senior executives, and an outstanding group of global institutional investors. Our Principals have worked with strategic investors for longer than almost anyone in the industry. Collectively, Health Velocity Capital’s investors represent organizations that. INSURE MORE THAN 175M AMERICANS OPERATE >700 HOSPITALS PROVIDE PHARMACY & PBM SERVICES TO 75% OF THE NATION EMPLOY 5.0M AMERICANS GENERATE $2.1T IN REVENUE We leverage these relationships to help drive revenue and build teams In a highly process-driven and symbiotic manner, our Principals have used their networks to tangibly create equity value at more than 95% of the companies with which they have partnered. 10,000+ CONVERSATIONS WITH STRATEGIC INVESTORS 1000+ COMPANIES DISCUSSED $40B+ EQUITY VALUE CREATION 100+ EXECUTIVES PLACED 200+ COMMERCIAL RELATIONSHIPS FACILITATED We’re an investment firm that is driven by purpose, a clear mission, and an important set of core values Our mission is to generate outstanding financial returns while being the preferred innovation partner of entrepreneurs and investors working toward a more affordable, sustainable, consumer-friendly healthcare system.

Our focus is on opportunities that are beyond proof of concept and poised for more significant development and growth in the Medical Device, Life Science Tool, Diagnostic and Digital Health sectors. Why Gilmartin Capital? The investing landscape is long on capital and short on insight. Our value extends beyond capital. We possess extensive domain expertise in areas such as strategy, market assessment, and capital markets advisory. Our passion is to avail our experience and network to help you solve problems, drive scientific discovery, help patients and grow. For over two decades, we have amassed a propriety expert network consisting of key opinion leaders across multiple therapeutic verticals and technical specialties, and best-in-class operators in various operational, scientific, and financial areas. In fact, the majority of our fund capital comes from operators like you. The founding partners have decades of experience analyzing and advising healthcare technology companies. We do the math! We want to help you advance your vision.

The T1D Fund invests in areas strategically aligned with JDRF, with an emphasis on cure-oriented or disease modifying therapies. The T1D Fund is an evergreen model and realized gains will be deployed into new investments. The T1D Fund was launched in 2016 and continues to grow its half-dozen person team and > $150 million assets under management. The Fund has made investments in approximately thirty portfolio companies and has already generated several successful exits. The Fund will continue to be a highly active investor playing various roles within its world-class co-investor syndicates. JDRF is the world’s largest nonprofit funder of T1D research having made grants of approximately $2 billion over the past fifty years, and the JDRF seeded the Fund with an initial investment capital and provides meaningful support and access to the key stakeholders and experts in the T1D community. Success is enhanced by the Fund’s relationship and leverage of JDRF resources, yet the Fund governed as a separate vehicle with an independent investment team, board, and investment committee, allowing for nimble and effective decision making. This new model has been highly visible, with coverage in outlets including the New York Times, Bloomberg TV, BioCentury, Venture Capital Journal, and Axios.

F2 Venture Capital is a Tel Aviv-based VC firm that invests in early-stage technology companies on the cutting edge. Our team members have been investors, operators, and engineers in startups and multinational giants that changed the game over the last twenty years. With $500 million assets under management, F2 powers visionary founders on their bold missions with personalized support. F2 also operates The Junction, Israel's most active pre-seed investment platform, to back founders with guidance, network, and capital from day zero. What does F2 stand for? F2 stands for “Power to Founders”. Our team is here to augment and support your team with the guidance, network and capital to hit your milestones and realize your vision. What are our core values? Our core values are trust, boldness and efficiency. All of our team members share these values that are inspired by the values that Israel’s special forces use to accomplish daring missions against all odds. When was F2 established? We launched our first fund in 2017. Our founders spun out of Genesis Partners, one of Israel’s most established and respected VC funds over the last 25 years. We are currently investing out of our second fund raised in 2019. Which notable companies have we backed? Our partners have previously backed Bizzabo, Click Software (Acquired by Salesforce), Crossrider (FTSE IPO), eToro, FundTech (NASDAQ IPO), Innovid, Kidaro (Acquired by Microsoft), Monday.com, Neebula (Acquired by ServiceNow), ObserveIT (Acquired by Proofpoint), Optimove, PrimeSense (Acquired by Apple), R2Net (Acquired by Signet) and Simplex, among many others from seed stage to exit. Who backs F2? We are backed by institutions and family offices on every continent except Antarctica. Many of our investors are successful founders themselves and routinely help our portfolio companies with advice and support on the ground. F2 is also supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments. Where do we focus? We back deep technology companies at the junction of Big Data, Artificial Intelligence and Connectivity. These are B2B or B2B2C enterprise software companies with R&D in Israel. Do we focus on particular industries? We believe technology will disrupt every market, so our approach is industry agnostic. We back companies in cyber security, digital health, financial services, HR, insurance, media, real estate, retail and software infrastructure, among other areas. We do not invest in hardware or biotech. At which stage do we invest? It is never too early to get in touch with our team. We love sharing ideas and tailor our approach to support founders at the concept, pre-seed and seed stages. How much do we invest? F2 typically leads seed rounds with checks of up to $4M. We reserve additional funds for follow on rounds in high growth companies. What do we look for in a startup? In order to take our investment decisions, we evaluate the team, market, value proposition, technology and commercial validation. The team is by far the most important factor for us. What do we look for in the team? We are looking for authentic entrepreneurs – women and men who could not imagine doing anything except their venture and have a large vision for their company. Founders should also complement each other in terms of technical and commercial skills. We also love to back “first timers”. What do we look for in the market? We are interested in game changing startups targeting large, existing markets like financial services and healthcare, or small but rapidly growing markets like artificial intelligence. What do we mean by value proposition? We are looking for compelling concepts with a clear business model and a unique approach to solving big problems. Timing is also critical; we ask, “why now?" What do we mean by technology? We look for startups whose technology can provide a moat or barrier to entry for competition and support a great product and user experience. What do we mean by commercial traction? We look for evidence of product-market fit. At the early stage, this usually comes in the form a small but passionate set of customers who view your service as “mission critical”. What is our investment process? Our investment process generally follows five steps: First meeting with our team. In advance of our first meeting, we will review any materials you want to share. This will help us ask the right questions to ensure there is a fit. Our first meeting (or call) will be 45 minutes to cover the basics and feedback. Follow up meetings with our team. Most of our “passes” happen after the first meeting. Follow up meetings mean we are genuinely interested in your startup and want to learn more. You will meet additional team members to address questions and concerns. It’s also our chance to share more about F2 and how we can help. Meetings with outside experts. Over the last 25 years, we have had the privilege to work with founders across every sector. We will match you with domain experts from our network who help us to build conviction and respond efficiently. Meeting with our Investment Committee. Our general partners comprise the investment committee of the fund. We meet every Monday and will invite you back to share the entire story and address the questions that arise in our process. Final Decision. We take all investment decisions as a team by unanimous vote of the general partners. Our goal is to give you a final decision within 24 hours following the meeting with our Investment Committee. How long does our process take? While we follow the same steps for every company, the timing of our process varies based on the investment criteria and our level of conviction. It can range from two weeks to two months but generally we strive to complete a thorough process as fast as possible. Is there a fast track? The Junction is our fast track to investment. The program is designed for strong founding teams that are still developing one of or more parts of their business plan. We can move as fast as one week to provide pre-seed funding in these situations. Does F2 only back companies from The Junction? No. F2 invests in the seed stage in companies from The Junction as well as directly into companies that do not start at The Junction. We harness the network of founders and partners around The Junction to support all of our companies. What is The Junction? Established in 2011 at Genesis Partners, The Junction is our pre-seed investment program to help founders achieve technological, product and business targets in an accelerated time frame. What are some notable companies from The Junction? The Junction has launched more than 200 companies including AppsFlyer, HoneyBook, Simplee, ClarityRay, HouseParty, CyberX, Mobilize and many others that have raised close to $1 billion from top VC funds and realized multiple exits to tech giants. What value does The Junction provide? Over a 6 month period, startups in the program receive tailor made support in strategy development, positioning, sales & marketing and recruitment, among other critical areas. The Junction provides 5 layers of support to founders: Guidance. Expert guidance from investors, alumni and industry experts. Network. Access to multinational partners for commercial pilots and investment. Capital. Pre-seed funding from F2 on founder-friendly terms. Operations. Support in positioning, business development and HR from industry experts. Perks. Free workspace, credits and discounts for cloud hosting and additional services. What are the terms of the program? The terms of the program are simple. F2 invests on a SAFE (Simple Agreement for Future Equity) that converts into your seed round at a discount with no cap on the valuation. In addition, F2 has the right to participate in your seed round, on the terms of the round. How do you apply to The Junction? Contact us with your background and vision and we will follow up with you within 48 hours. If your focus fits our areas of focus, we will invite you for a meeting and give you a decision within 7 to 14 days. Does F2 continue to invest in companies from The Junction? Yes. We can lead or join the seed investment round in companies from The Junction. In fact, this is why we run the program – to get to know you, add value and give you the opportunity to get to know us – to build a strong and successful partnership with you for the long term. How much do we invest in a company? F2 typically leads seed rounds with checks of up to $4M. We reserve additional funds for follow on rounds in high growth companies. Will F2 join a round with another VC? Yes. We often partner with other top funds, multinationals and strategic angels from our network and yours to build the best possible team and support your growth. What makes F2 different? F2 is a specialized fund with a clear mandate to back seed stage, deep technology companies in Israel. We are totally aligned to help you reach your milestones and bring additional top global funds for your round. In addition to our team of investment and HR professionals and portfolio companies, The Junction community with hundreds of founders and partners pay it forward to support you with collective wisdom and partnership. How do you support your companies? The companies we have previously backed have raised billions of dollars in follow-on capital. We leverage our experience and relationships – built over decades – to help you build the right pitch and connect with your ideal partner. As market conditions shift and Series A pools shrink, this kind of resource becomes a serious advantage to our founders. Will F2 support you in future rounds? On day one we set milestones together and help you achieve them. We want to be your first call when you hit an obstacle so there are no surprises, and we continue to invest in your Series A round and beyond as you execute on plan or pivot with the market. How does F2 help you with HR? Our Head of People is dedicated to help you connect and screen top talent to build your team. As a trained psychologist, she also coaches our founders through inevitable tensions and challenges in order to perform at your best, as individuals and as a team. Does F2 take board seats? F2 takes a board seat in companies when we invest at the seed stage and are most active helping you build your company in the first years. Outside of the board, we prefer to meet one-on-one to help you navigate challenges and opportunities on your growth trajectory.

At Flare Capital, we do more than simply provide capital for early stage and emerging healthcare technology companies. We partner with the most creative and passionate entrepreneurs aspiring to reinvent the business of healthcare. Together we work to build transformational companies that will profoundly improve the delivery and quality of healthcare while reducing costs. Our Team In 2014, Michael and Bill came together with the vision to build the leading dedicated healthcare technology venture capital firm. Both had started successful venture firms earlier in their careers and had a shared perspective on what the market now needed. As the “business of healthcare” is being transformed, there are significant opportunities to create important and enduring new healthcare technology companies. Given the complexity of this sector, a focused investment strategy with an experienced, committed team is required, and thus Flare Capital was launched. The firm is comprised of a number of proven healthcare technology investors with both deep industry knowledge and venture capital experience alongside accomplished operating executives of leading healthcare organizations. Our Executive Partners have substantial operating experience and our Industry Advisory Board includes many of the brightest healthcare minds with unique perspectives from across the industry. Together they provide critical insights and points of connectivity for our team at Flare Capital and are a tremendous resource for our entrepreneurs. Our Flare Scholars are professionals from preeminent healthcare companies and students from academic institutions across the country who scout interesting people and investment opportunities for us while learning about venture capital. Our Investors We have hand-assembled some of the most successful healthcare organizations, leading family offices, pension funds and investment companies as investors. At Flare Capital, we are privileged to partner with and have unparalleled access to leading innovative healthcare providers, payers, medical device companies, laboratory services provider, healthcare retailer, and one of the largest owners of healthcare campuses. Our investors have an enormous footprint in healthcare and are on the forefront of healthcare innovation. Our Approach We invest across the United States, recognizing that healthcare technology innovation is occurring in many cities around the country. While we consider ourselves principally early stage investors, we are full lifecycle investors. We partner with our entrepreneurs across the entire journey of company building. We are committed to our entrepreneurs and to being their first call, as we work closely and patiently through all strategic issues confronting our companies, maximizing their probability of success. In particular, we are very focused on assisting with recruiting and securing early customer validation and revenues. Starting and then scaling a successful healthcare technology company is hard. Careful and thoughtful financing strategies need to map to detailed product development timelines and other commercial milestones. We closely collaborate with our entrepreneurs to ensure that they have critical access to the best resources as the business scales. We relentlessly strive to be a true partner and to deliver extraordinary value to our entrepreneurs to enable them to build market leading, transformational businesses.